Sammanfattning
Th17 cells are essential for protection against extracellular pathogens, but their aberrant activity can cause autoimmunity. Molecular mechanisms that dictate Th17 cell-differentiation have been extensively studied using mouse models. However, species-specific differences underscore the need to validate these findings in human. Here, we characterized the human-specific roles of three AP-1 transcription factors, FOSL1, FOSL2 and BATF, during early stages of Th17 differentiation. Our results demonstrate that FOSL1 and FOSL2 co-repress Th17 fate-specification, whereas BATF promotes the Th17 lineage. Strikingly, FOSL1 was found to play different roles in human and mouse. Genome-wide binding analysis indicated that FOSL1, FOSL2 and BATF share occupancy over regulatory regions of genes involved in Th17 lineage commitment. These AP-1 factors also share their protein interacting partners, which suggests mechanisms for their functional interplay. Our study further reveals that the genomic binding sites of FOSL1, FOSL2 and BATF harbour hundreds of autoimmune disease-linked SNPs. We show that many of these SNPs alter the ability of these transcription factors to bind DNA. Our findings thus provide critical insights into AP-1-mediated regulation of human Th17-fate and associated pathologies.
| Originalspråk | Engelska |
|---|---|
| Sidor (från-till) | 4938-4958 |
| Antal sidor | 21 |
| Tidskrift | Nucleic Acids Research |
| Volym | 50 |
| Nummer | 9 |
| DOI | |
| Status | Publicerad - 20 maj 2022 |
| MoE-publikationstyp | A1 Tidskriftsartikel-refererad |
Finansiering
A.S. was supported by Erasmus Mundus Scholarship, University of Turku (UTU) and Council of Scientific and Industrial Research (CSIR), Government of India; S.K.T. was supported by the Juvenile Diabetes Research Foundation Ltd (JDRF) [3-PDF-2018-574-A-N]; S.G. received grants from the Centre of Excellence in Epigenetics program (Phase II) of the Department of Biotechnology [BT/COE/34/SP17426/2016], Government of India and the J.C. Bose Fellowship [JCB/2019/000013] from the Science and Engineering Research Board, Government of India; L.L.E. has received grants from the European Research Council (ERC) [677943]; Academy of Finland [296801, 310561, 314443, 329278, 335434, 335611]; Sigrid Juselius Foundation during the conduct of the study; L.L.E's research is also supported by University of Turku Graduate School (UTUGS), Biocenter Finland and ELIXIR Finland; R.L. received funding from the Academy of Finland [292335, 292482, 298732, 294337, 298998, 31444, 315585, 319280, 329277, 323310, 331790] by grants from the JDRF, the Sigrid Jusélius Foundation (SJF); Jane and Aatos Erkko Foundation, Diabetestutkimussäätiö, the Novo Nordisk Foundation and the Finnish Cancer Foundation; InFLAMES Flagship Programme of the Academy of Finland [337530]; University of Turku Graduate School [UTUGS]. Funding for open access charge: Academy of Finland and University of Turku.